Literature DB >> 12870574

Levetiracetam in the treatment of rapid cycling bipolar disorder.

Peter Bräunig1, Stephanie Krüger.   

Abstract

Levetiracetam (LEV) is a novel anticonvulsant that is currently investigated in bipolar disorder. It may be useful in the treatment of refractory and complicated cases, in which conventional mood stabilizers are not effective. We report two cases of rapid cycling bipolar disorder in which the add-on of LEV to a conventional treatment regimen improved symptoms of depression, as well as those of mania/mixed mania, and disrupted the severe rapid cycling pattern.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12870574     DOI： 10.1177/0269881103017002015

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN： 0269-8811            Impact factor:   4.153


  4 in total

1.  Levetiracetam as monotherapy or add-on to valproate in the treatment of acute mania-a randomized open-label study.

Authors:  Stephanie Krüger; Rahul Sarkar; Ramona Pietsch; Dirk Hasenclever; Peter Bräunig
Journal:  Psychopharmacology (Berl)       Date:  2008-03-28       Impact factor: 4.530

Review 2.  Benefit-risk assessment of levetiracetam in the treatment of partial seizures.

Authors:  Bassel Abou-Khalil
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  Potential of levetiracetam in mood disorders: a preliminary review.

Authors:  Anjana Muralidharan; Zubin Bhagwagar
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Rapid cycling bipolar disorder: Literature review on pharmacological treatment illustrated by a case report on ketamine.

Authors:  Alexis Bourla; Florian Ferreri; Thomas Baudry; Vincent Panizzi; Vladimir Adrien; Stéphane Mouchabac
Journal:  Brain Behav       Date:  2022-01-18       Impact factor: 2.708
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.